



Health & Medical Technologies

Singapore 2025

Global Business Innovation Programme



Innovate
UK



Contents

Introduction	04
Innovate UK	04
Innovate UK Business Growth	04
Global Business Innovation Programme	05
Health and Medical Technologies	06
Singapore and UK Co-operation	07
 Attending the visit.....	 09
 Companies.....	 10
Active Needle Technology	10
Ainostics	12
Asclepius MedTech	14
Biomex	16
Gampak	18
Garland Surgical	20
Health Navigator	22
Huru	24
MNS	26
PeriPear	28
PinPoint Data Science	30
Tend VR	32
Ufonia	34
Virilitas Labs	36
Walk With Path	38
 Notes.....	 40

Innovate UK

Innovate UK, part of UK Research and Innovation, is the UK's innovation agency. It works to create a better future by inspiring, involving and investing in businesses developing life-changing innovations. Its mission is to help companies to grow through their development and commercialisation of new products, processes and services, supported by an outstanding innovation ecosystem that is agile, inclusive and easy to navigate.

www.ukri.org/councils/innovate-uk



Innovate UK Business Growth

Innovate UK Business Growth is Innovate UK's national business growth and scaling service. It is an integral part of the innovation agency's products and services portfolio.

The service is available to all established small to medium sized innovation-focused growth companies, including Innovate UK grant winners.

Innovate UK Business Growth accelerates its ambitious clients on their growth journeys with one-to-one support from over 400 innovation and growth specialists and scaleup directors embedded in every UK region and nation. Their tailored, expert advice helps thousands of businesses sharpen their commercial strategies, realise the maximum value from their IP, raise game changing investment and take their businesses onto the global stage every year.

www.iukbg.ukri.org



Global Business Innovation Programme

Delivered by Innovate UK, the Global Business Innovation Programme is aimed at UK companies, helping them to establish international innovation collaborations and to overcome barriers to entering global markets.

This engaging programme consists of a get ready preparation phase, 5-day innovation visit to Singapore, an exploit the opportunity workshop, and support from an Innovate UK innovation and growth specialist - helping the business to identify growth opportunities and develop innovation led collaborations with partners in the country.



Health & Medical Technologies

A Thriving Ecosystem of Innovation and Collaboration

Singapore and the UK are at the forefront of global health and medical technologies, each offering unique strengths that foster growth, innovation, and economic value. Together, they present opportunities for collaboration, market expansion, and technological advancement.

Singapore: A Vibrant Hub for Health and Medical Technology

Singapore's health and medical technology sector spans advanced medical devices, diagnostics, digital health, and biotech. Home to all of the top 30 multinational MedTech firms, the country supports companies across R&D, product development, clinical trials, and manufacturing. In 2024, Singapore's MedTech manufacturing output reached S\$19.4 billion, reflecting the sector's continued growth and innovation. This achievement underscores Singapore's position as a leading hub for medical technology manufacturing in the Asia-Pacific region. The country's dynamic innovation ecosystem - with leading universities, more than 25 R&D centres, and numerous incubators—offers abundant opportunities for collaboration, pilot studies, and technology validation within Singapore itself. UK companies can engage directly with local partners, co-develop products, and access Singapore's sophisticated healthcare system as a testbed for next-generation solutions.

The UK: A Global Centre for Innovation

The UK's health and medical technology sector is equally exciting, contributing significantly to the economy and representing a major share of life sciences employment. SMEs make up over 85% of the sector, driving agile innovation in medical devices, diagnostics, digital health, and AI-enabled healthcare. In 2023, UK companies exported £10.1 billion in medical technology products, and UK-based inventors filed 5,918 patent applications at the European Patent Office (EPO).

The UK offers in-country opportunities for Singaporean companies to collaborate on cutting-edge research, access clinical expertise, and tap into well-established healthcare pathways. Its robust regulatory infrastructure, high-quality health data systems, and trusted healthcare providers make it an ideal environment to pilot, scale, and validate innovative health technologies.

Singapore and UK Co-operation

Both countries benefit from strong, supportive regulatory environments, with Singapore's Health Sciences Authority (HSA) and the UK's MHRA and NICE ensuring patient-focused innovation. Programs like the Global Business Innovation Programme (GBIP) bring UK and Singaporean companies together, facilitating in-country partnerships, joint R&D, and co-development projects. This creates a thriving, opportunity-rich landscape where companies can innovate, test, and grow within two of the world's most dynamic health and medical technology markets.







Hannah Thomas

Innovation Lead – Health Technologies
Innovate UK

 hannah.thomas@iuk.ukri.org

 www.linkedin.com/in/hannah-thomas-52067b59



Thierry Delange

Consortium Advisory Board Member & Partner Manager
Innovate UK Business Growth

 thierry.delange@iukbg.ukri.org

 www.linkedin.com/in/thierry-delange-09b0342b



Vanessa Wazny

Science, Innovation and Technology Advisor
British High Commission in Singapore

 vanessa.wazny@fcdo.gov.uk

 www.linkedin.com/in/vanessawazny



Trevor Marshall

Innovation Growth Specialist
Innovate UK Business Growth

 trevor.marshall@iukbg.ukri.org

 www.linkedin.com/in/trevorwm

Active Needle Technology



Muhammad Sadiq

+44 (0) 7906 880 699

muhammad.sadiq@activeneedle.com

www.activeneedle.com

**D5 Culham Science Centre, Abingdon Road,
Abingdon, Oxfordshire, OX14 3DB**



Profile

Active Needle Technology Ltd is pioneering next generation needle-based interventions through patented ultrasonic technology.

Our transformative devices enable safer, more precise, and less painful procedures, in oncology, vaccination, and medico-cosmetics. By replacing conventional needles with ultrasonically actuated solutions, we tackle critical challenges in treatment efficacy, needle placement, safety and patient experience.

Supported by strong intellectual property portfolio and international collaborations, ANT's highly experienced team is poised to disrupt multi-billion-dollar healthcare, cosmetic, aquaculture and adjacent markets.

Objectives

Our objective is to deliver safer, more effective alternatives to conventional needles, addressing critical needs in cancer treatment, vaccination, and medico-cosmetic care.

With cancer as Singapore's leading cause of death and a national focus on healthcare innovation, we see strong alignment. Singapore's strategic location, advanced MedTech ecosystem, and world-class research institutions make it an ideal partner for our cancer treatment technology, HyPerfuse Needle™.

Through this visit, we seek strategic collaborations, clinical partnerships, and financial support, with a long term vision of enabling in country manufacturing and contributing to Singapore's health innovation goals.



High value, needle-based solutions for medical, veterinary and cosmetic sectors

Active Needle is on a mission to improve clinical outcomes of needles in medicine and related sectors. Using patented ultrasound technology, the company targets sectors where its technology delivers significant value, leveraging the features of:


Greatly improved needle visibility

Easier penetration


Lower pain

Transformative drug delivery

Cancer treatment: Active Needle's direct-to-tumour injections reduce side effects and increase treatment efficacy. Shown to be vastly more effective in pre-clinical testing at treating cancer than conventional needle.



Drug + Standard Needle




Drug + Active Needle
Widespread tumour cell death

Vaccination: Increased perfusion and retention of vaccines increase effectiveness of DNA vaccines, opening new treatments and removing the need for antibiotics.



Injectate loss via needle track



Improved perfusion in target

AINOSTICS



Dr Hojjat Azadbakht

+44 (0) 782 558 0183

hojjat@ainostics.com

www.ainostics.com

3 Hardman Square, Spinningfields,
Manchester, M3 3EB



Profile

AINOSTICS™ is a medical AI company transforming the detection and management of neurological disorders. Our mission is to deliver faster, earlier, and more accurate diagnoses through advanced neuroimaging.

Our flagship product, BR[AI]N™, is the first and only FDA Breakthrough-designated software for predicting dementia risk from standard MRI scans, while also delivering insights across more conditions than any other product, including:

- Alzheimer's Disease,
- Multiple Sclerosis,
- Parkinson's,
- Traumatic Brain Injury,
- Normal Pressure Hydrocephalus,
- Brain Tumours,
- and Epilepsy.

Already adopted by the NHS and Texas Medical Center, BR[AI]N™ is positioned as the global standard in neurodiagnostics, optimising care and supporting emerging disease-modifying treatments.

Objectives

AINOSTICS™ aims to accelerate the adoption of BR[AI]N™, its FDA Breakthrough-designated neurodiagnostic platform, across Singapore and the Asia-Pacific region.

Through this visit, we will:

- Engage with clinical partners in Singapore to conduct validation studies and pilot deployments.
- Work with the Health Sciences Authority to define a clear regulatory approval pathway.
- Initiate commercial discussions with hospitals, healthcare providers, and regional distributors.
- Explore collaborations with leading research and academic institutions to adapt BR[AI]N™ to local needs and drive region-specific innovation.

Our goal is to establish a strong in-market presence and scale BR[AI]N™ to transform neurodiagnostic care across Asia-Pacific.



BRAIN™

AI Enabled Neuroradiology Platform

FDA

The Only Solution to Receive FDA Breakthrough Device Designation for Diagnosing Dementia Seven Years Before Clinical Symptoms Appear, Using Standard Non-Invasive MRI Scans

Capable of Generating 22 Detailed Reports from a Single Scan to Assist the Diagnosis of Conditions Such As:

- Traumatic Brain Injury
- Alzheimer's disease
- Multiple Sclerosis
- Brain Tumours
- Epilepsy
- Parkinson's

22

World's First Generative AI Engine to Deliver PET-like Biomarker Insights from Routine MRI Scans, Enabling Timely Prescription of Disease-Modifying Treatments Without the Cost or Risk of Invasive Procedures

GenAI



Asclepius MedTech



Michael Morgan-Curran

+44 (0) 754 073 7188

mm-c@asclepius-medtech.com

asclepius-medtech.com

12 King Street, Leeds, West Yorkshire,
United Kingdom, LS1 2HL



Profile

Surgery is often seen as safe with full recovery expected, but in reality, it carries high risks with around 1 in 3 patients experiencing complications that may cause lasting problems.

Despite advances in surgical and perioperative care, complication and readmission rates remain unchanged.

Current methods of assessing patient fitness for surgery are subjective, unreliable, and inconvenient.

To address this, Asclepius MedTech Limited has developed **Surgfit™**, the world's first remote, patient-friendly and more cost-effective preoperative assessment system.

Surgfit™ is clinically validated and provides a superior, accessible alternative to traditional in-hospital assessment, improving how patients are evaluated before surgery and reducing risk.

Objectives

Our goal is to meet the urgent need by hospitals and clinicians for better, more accurate, inclusive and convenient fitness-for-surgery assessment. That supports hospitals' shift toward community-based patient-centered, digital assessment.

Surgfit™, designed by surgeons and anesthetists, uses our wearable biosensor paired with our patient app hosting functional capacity questionnaires, replacing hospital-based tools and consultations.

It collects richer longitudinal data sets, supports better clinical decision-making, and enables tailored surgical care. Enhanced with predictive software, it improves risk stratification to reduce risks, optimize recovery, shorten hospital stays, and lower readmissions—driving efficiency and cost-savings across surgical care pathways and improving patient experience.



80% of us will have at least 1 major surgery in our lifetime

500 million surgeries performed globally annually



25 - 44% of surgical patients experience complications*

15% of patients are readmitted to hospital*

Cost per readmission **S\$ 16,037****

11 - 19% mortality rates*

*Singapore MoH surgical performance data

**Mean cost per patient

Surgfit

Remote **'At Home'** Assessment

Clinically
Validated

5 more patients assessed in the time taken to assess 1

Requires 1 health professional

Takes 15 - 30 minutes to fit

Install in hospital clinics, pharmacies, Gp practices, care homes or at home

Eliminates
80% of the time
and 50% of the cost
of preoperative
assessment

Reimagining Surgical Preoperative Assessment
Safer more effective surgical care



Biomex



Lance Rane

+44 (0) 789 041 3322

lance@biomexlabs.co.uk

www.biomexlabs.co.uk

**167-169 Great Portland Street,
5th Floor, London, W1W 5PF**



Profile

Biomex is developing the next generation of wearable tech for rehabilitation in athletes following anterior cruciate ligament injury and patients with knee osteoarthritis, global markets worth \$1b and \$47b respectively.

Based on patented technology developed at Imperial College London, its first product, BioStim, combines an embedded AI-based control system with neuromuscular electrical stimulation to advance a new paradigm for musculoskeletal rehab, enabling direct realtime training to restore normal movement and reduce pain.

BioStim is currently undergoing clinical trial with the Royal Dutch Football Association, with product launch due in 2026.

Objectives

Clinical validation

We are actively seeking clinical partners to host validation activities of our devices in patients with anterior cruciate ligament injury and knee osteoarthritis.


New applications

Our technology provides a way to measure and modify human movement in real time, and we are interested in collaborations based on exploring new applications.

Investment

We are actively seeking investment to complement grant funding from Horizon Europe in order to accelerate clinical validation and go-to-market.

BIOMEX.



**SENSOR-BASED MOVEMENT
ANALYSIS 200X PER SECOND**

**REALTIME MUSCLE
ACTIVATION**



**TRADITIONAL PHYSIOTHERAPY IS INEFFICIENT.
BIOSTIM COMBINES NEUROMUSCULAR ELECTRICAL STIMULATION
WITH AI FOR DIRECT RE-EDUCATION OF MOVEMENT.**

Musculoskeletal conditions affect over 1.5 billion patients globally. BioStim represents a new paradigm in physical rehabilitation for these patients, based on years of research at Imperial College London.

Traditional physiotherapy relies on verbal feedback on movement quality from clinician to patient. BioStim changes this, using neuromuscular electrical stimulation to correct movement directly and autonomously, in response to a realtime feed of motion data and according to the specific needs of the clinical team.

Currently in clinical trial with the Royal Dutch Football Association, BioStim will launch in 2026 for the sports injury market, with osteoarthritis and neurological conditions to follow. Get in touch to discuss collaborations and partnerships.

Gampak



Gavin Scott

+44 (0) 773 065 7354

gavin@gampak.co.uk

Gampak.co.uk

Gampak Limited, Highbank Office, Halton Street, Hyde, Cheshire, England, SK14 2NY



Profile

Gampak Ltd is a UK-based medical technology company pioneering the Tri-Test™ platform, a next-generation lateral flow diagnostic delivering superior accuracy, consistency, and usability.

Our flagship programme, Project P.R.I.S.M., applies this innovation to the early detection of pancreatic cancer using proprietary biomarkers in partnership with BPG Bio (USA). Pancreatic cancer has a survival rate of just 10% due to late diagnosis, yet when detected early and treated promptly, survival can exceed 80%.

By enabling earlier detection, Gampak aims to transform outcomes in one of the world's deadliest diseases.

Objectives

Our objective in Singapore is to secure partners and investment to advance Project P.R.I.S.M., the development of multi-biomarker assays for the early detection of pancreatic cancer.

We are seeking investors who can support the scale-up and commercialisation of our technology, and partners with expertise in diagnostics, biotech, and healthcare to help refine and expand our assay platform.

By collaborating with Singapore's world-class life sciences and investment community, we aim to accelerate development timelines and bring a transformative diagnostic solution to global markets.






Pancreatic Cancer Rapid Diagnostic

Pancreatic cancer has one of the lowest survival rates of major cancers - Around 10%

If diagnosed at its earliest stages treatment can bring the survival rate up to **80%**.

Gampak is developing a rapid diagnostic test capable of detecting pancreatic cancer at all stages - Delivering results in **under 10 minutes**.

With its low cost and simple design, the Gampak test enables mass screening of high-risk groups worldwide, both at the point of care and in the home.




The Gampak blood test is supported by proprietary multi-omics biomarker data - A dataset derived from one of the world's largest biobanks and curated through advanced AI-driven analytics. This data identifies and validates highly specific biomarker signatures for pancreatic cancer, inaccessible to other commercial developers.

Product options include a quantitative point of care test providing detailed results via a handheld reader and mobile device/pc app and a simple qualitative lateral flow signpost test.

Reader: Connected by USB or Bluetooth



Test Card: Inserted into the reader



Results App: Provides detailed results for each biomarker and overall results

Garland Surgical



Simon Mifsud



+44 (0) 797 115 4703



simonmifsud@garlandsurgical.health



www.garlandsurgical.health

**Lower Gurnox, Easinghope Lane,
Worcester, UK, WR6 5PA**



Profile

Garland Surgical is commercialising MaltaHip, a patented hip implant developed from first principles at Malta University. Unlike traditional ball-in-socket implants, MaltaHip's triaxial design—inspired by the ankle joint—uses three unidirectional articulations to mimic natural movement, drastically reducing wear and extending implant lifespan to over 50 years.

A unique interlocking mechanism improves stability, lowering dislocation risks while enhancing range of motion. This enables younger patients to undergo hip replacement without later revisions. Fewer revisions and admissions generate cost savings and reduce clinical waste. Based in the UK and Malta, Garland partners with global experts to deliver sustainable, life-changing orthopaedic innovation.

Objectives

Garland Surgical's objective for the GBIP Singapore trip is to establish strategic partnerships, advance regulatory clearance, and unlock market access for MaltaHip, its next-generation hip replacement.

The company aims to connect with leading Singaporean centers of excellence, healthcare providers, and industry clusters to pilot and validate its device, identify regional manufacturing and distribution allies, and secure investment.

This visit supports scaling up manufacturing, clinical adoption, and sales, bringing innovative hip technology designed for deeper flexion and Asian lifestyles to Southeast Asia's fast-growing patient populations.



PIONEERING A REVOLUTION IN HIP REPLACEMENT SURGERY



OUR MISSION

We are pioneering a revolution in hip replacement with MaltaHip - a patented, 'tri-axial' implant designed for unmatched stability, ultra-low wear, and lifetime durability. MaltaHip is engineered to support patients of all ages, activity levels, and backgrounds: true movement without compromise.

CURRENT CHALLENGE

40 million people worldwide suffer from hip arthritis; aging and activity trends are accelerating numbers.

2M	10%	42%	200K
hip replacements per year	Dislocate within 2 years	Fail within 25 years	Revision surgeries per year

Modern patients: demand a higher performance from their hip implant. They want to be able to hike, play golf, or do yoga without compromise and lead full and active lives.



OUR VALUE PROPOSITION



Mobility with Stability: Patients can return to their chosen activities, moving freely and living fully.



Lifetime Durability: Projected to halve revision surgeries with its game-changing technology, MaltaHip is the first 'hip for life.'



Improved Health Economics: MaltaHip has the potential to reduce global revision surgery costs by up to £1B.

OUR SOLUTION

Inspired by the ankle, a naturally durable joint, **MaltaHip** features three unidirectional articulations that mimic real joint motion, providing a breakthrough over the traditional ball-and-socket design.

What sets MaltaHip apart?

- Unmatched Stability:** Cadaveric studies show MaltaHip delivers excellent stability, allowing extreme joint angles without dislocating.
- Superior Range of Motion:** Increased functional movement for today's active patients.
- Lab-Proven Performance:** Independent tests (EndoLab®, Germany) show 75% less wear than leading contemporary implants*.
- Universal Patient Fit:** Safe and effective for patients of any age, gender, or ethnicity.

**Independent EndoLab® (Germany) testing, 2024: MaltaHip demonstrated 75% less wear vs. contemporary leading hip implants under ISO 14242-1 simulation.*

This document is non confidential and provided for information purposes to current and prospective investors. Full technical, regulatory, and commercial details available upon request.



6
TRL level

50+
years implant
lifetime

75%
less wear



GET IN TOUCH

to explore collaboration and
partnership opportunities

Contact: Simon Mifsud, CEO
simonmifsud@garlandsurgical.health
www.garlandsurgical.health



Health Navigator



Joachim Werr



+46 706266571



joachim.werr@hn-company.co.uk



www.hn-company.co.uk

**Hale House, 76 Portland Place, London,
England, W1B 1NT**



Profile

We help people take control of their health and stay out of hospital. We use a clinically validated AI algorithm to identify patients at rising risk of extended hospital stays.

Over the past decade, we have developed a person-centred coaching methodology and technology platform, delivered by NHS Personalised Care Institute-accredited clinical coaches, to support individuals on their health journeys.

Clinician-founded and clinician-owned, we operate across England and the Republic of Ireland to deliver our tech-enabled service at scale. In partnership with the NHS, we run one of England's largest Real-World Evidence programmes, focused on preventing unplanned hospital care and improving outcomes for patients and health systems alike.

Objectives

We believe that every one of us can take control of our health and live a healthier, happier and more fulfilled life. At Health Navigator, our mission is to transform how healthcare systems respond to rising demand by focusing on the small proportion of patients who drive the majority of resource use.

We recognise that high-need patients are often transient, with most returning to lower levels of care within a year. Our objective is to predict these changing risks and needs, enabling the right service to be delivered to the right patient at the right time. By doing so, we strive to improve patient journeys, achieve better clinical outcomes, and ensure healthcare resources are used more effectively and sustainably.




Health Navigator



In developed economies 1% of population consume about 90% of unplanned hospital care. Most of it is predictable and preventable.

We use a clinically validated AI to find patients at rising risk of experiencing an extended stay in hospital, and offer them a virtual behavioural change clinical coaching solution.



We've spent a decade developing a person-centred coaching methodology and technology platform which our NHS Personalised Care Institute accredited clinical coaches use to support each individual's personal health journey.

SIGNIFICANT SAVINGS AND IMPROVEMENTS IN PATIENT OUTCOMES

-25%
bed days

-34%
emergency
attendances

-24%
unplanned
admissions

+19%
survival rate

Huru



Joshua Eggleston

+44 (0) 759 540 1128

josh@hurulabs.com

www.hurulabs.com

20-22 Wenlock Road, London, England,
N1 7GU



Profile

Globally, 65 million people have epilepsy, but 5.4 million are misdiagnosed. Standard Electroencephalography (EEG) recordings are just 17% accurate. While multi-day in-clinic monitoring can achieve 90% accuracy, it is too expensive and capacity-constrained for widespread use.

At Huru, we're addressing this crisis with Clic EEG, the world's first patient-applied EEG medical device, matching the accuracy of multi-day in-clinic systems. A highly scalable, home-based solution.

Currently deployed by leading UK and US universities for research, supported by Gates Foundation, Wellcome Trust and the NHS.

With FDA submission due end-2025, we're positioned for US Validation in 2026 and Go-to-market in 2027.

Objectives

Huru is establishing Singapore as our Asia-Pacific hub for manufacturing and commercial launch.

We are seeking:

1. Validation partners to complement our US/UK studies
2. Distribution partners for ASEAN market entry
3. SEED investors for our 2026 launch post-FDA

Our mission is to support accurate diagnosis, addressing the urgent unmet need for 15 million people in Southeast Asia with epilepsy. We aim to close the ASEAN treatment gap (typically 80-90%) and high misdiagnosis rates with the support of Singapore's vibrant medtech ecosystem.

We also welcome opportunities to collaborate on clinical trials and translational research across the region.

huru
Neuromonitoring at scale

Clic[®] EEG

The worlds first patient-applied EEG medical device

Co-designed by people with Epilepsy,
delivering multiple day in-clinic
accuracy at home.



Reduced
time



Reduced
cost



Improved
Comfort



Improved
accuracy



Optimised
treatment



Greater
Convenience



ROUTE TO MARKET:

2025

2026

2027



SEED



UK
CE

TRUSTED BY:



Gates Foundation



Rosetrees
Supports the best medical research



University
of Exeter



University Hospitals
Bristol and Weston
NHS Foundation Trust



MNS



Henry Dunne

+44 (0) 753 924 3546

henry.dunne@microneedlesolutions.com

www.microneedlesolutions.com

**Nexus Discovery Way, University Of Leeds,
Leeds, England, LS2 3AA**



Profile

MNS is a UK-based lifescience company pioneering dissolvable microneedle patches that deliver vaccines and therapeutics painlessly, without cold-chain storage, sharps disposal, or the need for trained personnel.

The platform is designed to be compatible with a wide range of medicines, offering a cost-effective, patient-friendly alternative to injections. With strong intellectual property, successful preclinical studies, and validation from leading healthcare stakeholders, MNS is preparing for clinical trials in collaboration with the NHS.

Our goal is to transform global drug delivery by making access to life-saving medicines more equitable, sustainable, and efficient.

Objectives

Through GBIP Singapore, MNS aims to establish strategic partnerships to accelerate clinical and commercial adoption of its Miracus™ microneedle platform.

Our objectives are to secure Phase 2 trial collaborations with leading sites such as SingHealth IMU and NUHS, engage the Health Sciences Authority to define the regulatory pathway for microneedle-based delivery in Asia-Pacific, and meet regional HQs of Pfizer, GSK, AstraZeneca, Novartis, and Hilleman Labs to explore licensing and co-development.

We also intend to identify regional manufacturing partners to support APAC expansion. These outcomes will position MNS for rapid market entry and international growth.





Miracus™ Platform, Transforming Global Vaccine and Therapeutic Delivery

Painless, self-administered,
cold-chain free



Microneedle Solutions has developed the Miracus™ platform – dissolvable microneedle patches for vaccines and therapeutics.



5-minute
Wear Time



No Sharps
Waste



100%
Painless



Thermally
Stable



Eco
Friendly

Our platform removes barriers to medicine access by eliminating cold-chain, needles, and the need for trained personnel. Designed for scale and sustainability, it supports low- and middle-income countries and helps to reduce global health inequalities.

TESTIMONIALS

- Wes Streeting, UK Secretary of State for Health & Social Care:
“That could be world-leading, game-changing technology.”
- MHRA CEO: “Very exciting – great technology potential.”

Microneedle Solutions – Enabling equitable global access to medicines.

✉ Henry.dunne@microneedlesolutions.com

🌐 www.microneedlesolutions.com



PeriPear



Eviatar Natan

+44 (0) 7540 518 213

eviatar@peri-pear.com

www.peri-pear.com

105 Godstow Road, Wolvercote, Oxford,
England, OX2 8PF



Profile

Our mission is to reduce perineal injuries during childbirth that lead to immense physical and psychological consequences. In Singapore, the direct healthcare costs of perineal tears are significant, encompassing initial treatment, pain management, infections, readmissions, pelvic floor therapy, and long-term complications. Costs rise with severity, but even second-degree tears, often considered "normal", can lead to chronic trauma. These issues increase healthcare costs and contribute to postpartum dissatisfaction and maternal morbidity.

Peripear's core team combines deep domain expertise in women's health, regulatory strategy, finance, hardware development, and commercialisation: uniquely positioning us to address the maternal health gap in the Singapore market.

Objectives

In the next 12 months, Peripear will be used to reduce severe perineal injury across 3 countries. At a \$195 price point, we project up to 800% ROI by reducing 2nd–4th degree tears by 60%. By exploring potential pilot partnerships with leading maternity hospitals, we close critical information gaps in labor and delivery protocols, barriers to adoption among clinicians, and patient expectations.

Peripear is also eager to engage with investors and innovation leaders who are aligned with women's health equity and maternal safety to drive commercial traction and to reduce avoidable harm in childbirth.






peripear

90%

of vaginal births lead to tearing
We're here to change that.
Because birth should empower, not injure



A pioneering FemTech solution offering a smart, wearable device designed by a practicing midwife to reduce perineal tearing during vaginal birth.

“Thank goodness! I have been waiting for someone to make this!”

Julie Hakim, MD, FRCS(C), FACOG Baylor College of Medicine, USA

Winners: “Most Potential to be Revolutionary to Women’s Health in the UK” Innovate UK/NHS Accelerating Femtech Programme 2025



**Accelerating
FemTech**

SEIS Investee of the Year 2025 Award



Royal College of
Obstetricians &
Gynaecologists

PinPoint Data Science



Nigel Sansom



+44 (0) 796 836 7888



nigel.sansom@pinpointdatascience.com



www.pinpointdatascience.com

Nexus, Discovery Way, Leeds, LS2 3AA



Profile

PinPoint Data Science is a UK company developing AI-enabled blood testing for multi-cancer detection. The 'PinPoint Test' is a platform for risk management and intelligent triage of suspected cancer patients by individual risk – one simple blood test to improve patient outcomes and reduce systemic pressure in healthcare services.

Developed in collaboration with NHS England, the University of Leeds and with support from Innovate UK, PinPoint is built on data from almost 400,000 patients. It has applications in triage for hospitals, cancer screening, and the health check and insurance industries. More intelligent, more efficient, better outcomes.

Objectives

Each of us will be affected by cancer at some point in our lives. At PinPoint, we want to transform the way healthcare systems deal with suspected cancers to build a more efficient and safer service for us all. Our mission is to be a cornerstone of the digital healthcare systems of the future – unlocking the data in our blood for a new generation of AI-enabled clinical tools.

In Singapore we aim to build connections with potential regional partners and meet investors interested in joining us on our journey.

pinpoint



intelligent tools for cancer detection

50% of us will be affected by cancer at some time in our lives.

At PinPoint, we aim to make sure that when that day comes, the healthcare system you rely on has the tools it needs to detect, diagnose and treat cancers quickly.

AI-driven blood testing to focus clinical resources where they are needed most, when they are needed most.

The PinPoint Test is a UKCA-marked Software IVD that uses machine learning to analyse standard blood biomarkers and generate a risk score for cancer.

Developed and validated in the NHS, PinPoint offers intelligent tools for triage of symptomatic patients - flagging low risk for rule-out and high risk for rapid investigation.

We are now looking for strategic partners to accelerate localisation and deployment of the PinPoint Test in new markets across Asia, and for investment to support the next generation of PinPoint intelligent tools: multi-cancer screening in one simple blood test.



[Scan here to learn more:](#)



Tend VR



Dr Kim Bevan

+44 (0) 787 058 5652

kim@tend-vr.com

www.tendmentalhealth.com

**Tend VR Ltd, Studio 307 Netil Corner, 89-115
Mare Street, London, UK, E8 4RU**



Profile

Tend are leading the way in creating scalable, clinically validated immersive treatments, starting with our Class I depression and anxiety intervention, currently deployed by the NHS.

Tend's virtual reality (VR) adaptation of Mindfulness Based Cognitive Therapy (MBCT) is a revolutionary new way to help people with depression and anxiety, delivered to patients in the community or at home.

At up to five times cheaper than CBT, Tend VR-MBCT can be deployed rapidly at scale. We're creating what will become one of the best digital treatments for depression, at a price point that is radically cheaper than talking therapies.

Objectives

More than half a billion people suffer from depression and anxiety, with an estimated \$97billion in direct expenditure on treatment by healthcare systems globally.

Our vision is to provide cutting edge digital therapies to the hundreds of millions of people across the globe who require better mental health treatment, at a price affordable to all.

Tend are seeking research and delivery partners to scale rapidly with us, taking our groundbreaking mental health intervention directly to people where they need it. With just 5,000 Tend headsets we can deliver an intervention to 1,000,000 people a year.





Tend VR-MBCT

A groundbreaking,
highly affordable
depression
intervention now
available on the NHS



1st VR-MBCT deployed in the NHS

Up to 5 times cheaper than talking
therapies

50% reduction in depression and
anxiety scores

1 headset can deliver an intervention
to 200 patients a year

**Our goal is to
transform mental
health treatment
across the world**

Contact us to find out how we can tackle the mental health
crisis together www.tendmentalhealth.com



Ufonia



Yajie Vera He

+44 (0) 785 222 1241

yh@ufonia.com

ufonia.com

104 Gloucester Green, Oxford, UK, OX1 2BU



Profile

Ufonia is a health technology company pioneering clinical artificial intelligence. Our flagship product, Dora, is a UKCA/CE-marked voice assistant that automates routine clinical conversations by telephone, requiring no apps or internet access.

Deployed across 18+ NHS sites with over 100,000 consultations delivered, Dora frees clinical time and achieves high patient satisfaction. Our multidisciplinary team combines healthcare expertise with world-class AI innovation, with research published in leading journals and conferences.

We are expanding globally with a U.S. office, partnerships across Europe, Asia, and North America, and proven success through a clinical trial at the University of Toronto.

Objectives

Ufonia's objective is to transform patient access to healthcare while setting the global benchmark for safe clinical automation. We aim to expand Dora's deployment in diverse health systems, transforming care pathways such as long-term condition monitoring and surgical follow-up.

At the same time, we are advancing multilingual, empathetic AI capabilities and validating them through collaborations with international academic and clinical partners.

By combining innovation with equity, we seek to reduce clinician workload, enhance patient experience, and build global confidence in regulated, next-generation AI for healthcare.



We don't have enough healthcare workers

Today, medical visits are severely constrained, with a projected global shortfall of 10 million healthcare workers by 2030 (WHO).

This is why we built Dora, our **Conversational AI**

Dora is a medically regulated, multilingual AI agent that automates routine clinical conversations over the phone. It works across multiple clinical pathways, empowering clinicians to work at the top of their license.

15%

of England hospitals
use Dora

100,000+

calls completed
in the UK

91%

patients rated
Excellent satisfaction



Our global journey

We have formed research and commercial partnerships across four continents, and published at top clinical and AI conferences. We'd like Singapore to be part of our global journey.

Virilitas Labs



Daniel Marcu

+44 (0) 747 944 7613

daniel@virilitaslabs.com

www.virilitaslabs.com

**Centrum Building, Norwich Research Park,
Colney, Norwich, England, NR4 7UG**



Profile

Virilitas Labs is a UK medtech company transforming male reproductive healthcare. With fertility rates in Southeast Asia falling below 0.9 children per woman (vs. 2.1 replacement) and 1 in 6 couples affected by infertility, the need for innovative solutions is urgent.

Half of infertility cases are male factor, yet men face delays of over three years before diagnosis, reducing treatment success. Virilitas is developing first-in-class AI driven point-of-care fertility tests that deliver accurate results within minutes at home, supported by a digital app.

Backed by strong IP, clinical partnerships, and early investment, we are redefining male fertility diagnostics and digital health.

Objectives

Our goal is to accelerate the global launch of our at-home male fertility diagnostic kit and companion app. We aim to establish R&D partnerships for validation and clinical performance testing, secure distribution pathways, and international regulatory approval. By leveraging AI and scalable diagnostic chemistry, we seek to make male reproductive health testing affordable, accurate, and accessible to millions of men worldwide. Singapore offers a strategic hub for collaboration with diagnostics companies, healthcare providers, and investors to expand Virilitas Labs into markets where fertility and population growth are urgent national priorities.



Discover the Future of Male Fertility Diagnostics & Care

Rapid multi-analyte
semen testing in minutes

Aligned with WHO and
clinical fertility standards

AI-powered personalised
fertility insights

End-to-end
support through
our digital hub



Seamless EHR integration
for clinical use

Accessible anytime,
anywhere via our
companion app



"I've been supporting Virilitas Labs' point-of-care device from the start and am excited by its progress. This product has strong potential for OTC sales, distribution through intermediaries, and use in clinical settings — saving time, reducing costs, and speeding up diagnosis and treatment."

Dr Thanos Papathanasiou
CEO and Medical Director

Bourn Hall
FERTILITY CLINIC

Learn more



Supported by



Innovate
UK



Medical
Research
Council



ANGLIA
CAPITAL GROUP

Walk With Path



Lise Pape

+44 (0) 797 684 2669

lise@walkwithpath.com

www.walkwithpath.com

54 Sun Street, Waltham Abbey, Essex,
England, EN9 1EJ



Profile

Walk With Path is a mobility company dedicated to providing simple solutions that are clinically proven to solve unmet challenges. Path Feel, the flagship product, is a smart wearable that 1) conducts clinically validated gait analysis, and 2) can help detect and prevent diabetes foot ulcers.

The wearable connects to a user-facing smartphone app, which relays data to the cloud, from where it can be visualized by a clinician in a web-based dashboard. The product is in NHS pilots right now and will be piloted in the US from March 2026. Here it will be with reimbursement by Medicare.

Objectives

Walk With Path aims to transform mobility care with clinically validated wearables.

Our objectives are to:

- (1) deliver proven solutions that prevent diabetic foot ulcers and support gait analysis;
- (2) empower users to maintain independence and improve quality of life;
- (3) equip clinicians with actionable data for timely interventions;
- (4) secure integration and reimbursement through NHS and Medicare pilots and Singapore and Southeast Asia's health systems; and
- (5) scale globally through partnerships, making our technology accessible and impactful for patients and healthcare systems alike.




Every 20 seconds someone loses a toe, foot or leg due to diabetes

The costs of ulcer care is over \$100B every year in the US


Our remote monitoring solution solves this through continuous tracking of the biomarkers, with alerts provided to patients and clinicians to facilitate prevention of diabetes foot ulcers



Data is tracked continuously in real-time



Data is analysed using AI to predict and prevent ulcers from forming



- FDA registration complete
- Launching in the US in early 2026 with strategic partner
- Product in NHS pilots in the UK
- Seeking **strategic partnerships** in Asia
- Currently **raising a seed round**

Lise Pape
Founder
+44 (0) 7976842669
lise@walkwithpath.com

www.walkwithpath.com

A mobility company

Notes

[illegible]

Notes

This image shows a single sheet of white paper with horizontal blue or grey ruling lines. The lines are evenly spaced and run across the width of the page. There are no margins, text, or other markings on the paper.

Notes

This image shows a single sheet of white paper with horizontal blue or grey ruling lines. The lines are evenly spaced and run across the width of the page. There are no margins, text, or other markings on the paper.

Disclaimer

Whereas every effort has been made to ensure that the information in this document is accurate, Innovate UK does not accept liability for any errors, omissions or misleading statements, and no warranty is given, or responsibility accepted as to the standing of any individual, firm, company, or another organisation mentioned.

Copyright © 2025 Crown Copyright | All Rights Reserved.

You may re-use this publication (not including logos) free of charge in any format or medium, under the terms of the Open Government Licence. To view this licence visit: www.nationalarchives.gov.uk/doc/open-government-licence or email: psi@nationalarchives.gsi.gov.uk.

Where we have identified any third-party copyright information in the material that you wish to use, you will need to obtain permission from the copyright holder(s) concerned. Any enquiries regarding this publication should be sent to contact@innovateukedge.ukri.org.

Published in November 2025 by Innovate UK.

